LEADING EXTRACELLULAR VESICLE RESEARCH TOWARDS THE NEXT GENERATION OF TREATMENTS AND DIAGNOSTICS
With
Associate Professor Joy Wolfram, Group Leader,
Australian Institute for Bioengineering and Nanotechnology,
School of Chemical Engineering, University of Queensland
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Brisbane | May 2025
Joy Wolfram is an Associate Professor at the Australian Institute for Bioengineering and Nanotechnology and the School of Chemical Engineering at the University of Queensland in Australia. Originally from Finland, she earned both her bachelor’s and master’s degrees in biology before transitioning to engineering with a PhD in nanotechnology completed in China. Wolfram has over a decade of experience working in hospitals in the United States before joining the University of Queensland.
Her research focuses on extracellular vesicles, which are crucial for cell communication both locally within tissues and over longer distances between organs. Her lab studies the roles of these vesicles in both health and disease, particularly in cancer. They investigate the harmful messages released by cancer cells that aid in tumour growth, specifically in breast cancer, while also exploring how to harness beneficial extracellular vesicles from healthy individuals as potential therapeutics.
Wolfram’s lab is currently funded by the National Breast Cancer Foundation for a four-year project aimed at understanding how breast cancer-derived vesicles evade the immune system. Collaborations with the Faculty of Medicine and hospitals in the U.S. enhance her research efforts. Additionally, partnerships with local industries in Brisbane, supported by the Medical Research Future Fund, promote academia-industry connections. Notably, funding from Health Translation Queensland allows her to compensate patient advocates who contribute valuable insights and direction to her research.
Source: Written by AUDIENCED from transcript
You Might also like
-
Australian Healthcare Week 2019: Pitch Fest Finalist Coviu
Telelheath startup company Coviu was a Pitch Fest Finalist at last week’s Australian Healthcare Week Expo in Sydney. The Coviu platform has been developed as an spinoff from CSIRO and allows healthcare businesses offer video consultations to their own patients. It differs from being just a ‘talking head’ platform that Skype or Zoom could offer, by providing clinical tools integrated within the app. Anne Dao spoke with Co-founder and CEO Silvia Pfeiffer about the company and platform’s journey to date and its longer term goals.
Coviu helps healtcare businesses by helping fit in more consultation during that day and reducing no-shows for appointments. Also given the nature of the dispersed population, the application reaches to rural and regional areas where patients are a long distance from their healthcare provider. The company is focused on the Australian market and aims to enter the US market next year
Post Views:
3,007 -
New research papers show productivity gains and gaps
Commissioner Catherine De Fontenay talks about the Productivity Commission’s new approach to analysing health productivity, shifting the perspective from the unit measurement of individuals using the health system to the actual improvement of health. This has shown Australia’s health treatment productivity is improving, but identifies gaps in preventative health measures and duplication, where digital technology needs to be more effectively used.
-
Mission to raise awareness of sarcoma and need for clinical trial funding
Sarcoma, a rare and aggressive cancer, remains the deadliest cancer for children and young adults, accounting for nearly one third (30%) of cancer-related deaths among those aged 15–24 and one tenth (10%) of those aged 0–14. Further, still severely under-diagnosed, sarcoma only accounts for one sixth (15%) of all cancer diagnoses in the 15 – 24 age group, and less than a tenth (8%) among children under 10.